In a woman with polycystic ovary syndrome who has a first-degree relative with venous thromboembolism before age 60, what contraceptive regimen is recommended?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Contraceptive Regimen for Women with PCOS and Family History of VTE

In a woman with PCOS who has a first-degree relative with venous thromboembolism before age 60, progestin-only contraception (microdose or macrodose) or a levonorgestrel IUD should be prescribed as first-line contraception, avoiding combined estrogen-progestin contraceptives.

Primary Recommendation

A family history of thromboembolic events in a first-degree relative before age 60 is a relative contraindication to estrogen-progestin contraception 1. The presence of PCOS adds additional thrombotic risk, as women with PCOS have a baseline 1.5-fold increased risk of VTE even without oral contraceptives, which increases to 2-fold when combined oral contraceptives are added 2.

The first-line option for these women is microdose or macrodose progestin-based contraception 1.

Specific Contraceptive Options

Preferred Methods (No Increased VTE Risk):

  • Progestin-only pills containing desogestrel 75 mcg or levonorgestrel 30 mcg - these show no significant increase in VTE risk (OR: 1.45,95% CI: 0.92-2.26) 1
  • Levonorgestrel IUD - no excess VTE risk noted, with relative risk of 0.61 (95% CI: 0.24-1.53) 1, 3, 1
  • Copper IUD - non-hormonal option with no thrombotic risk 3

Methods to Avoid:

  • Combined estrogen-progestin contraceptives (pills, patches, vaginal rings) - formally contraindicated given family history 1
  • Depot medroxyprogesterone acetate (DMPA) - shows increased VTE risk (RR 2.67,95% CI: 1.29-5.53) similar to combined oral contraceptives 3
  • Transdermal patches and vaginal rings - increase thromboembolism risk by 3-4 fold 1

Additional Considerations for PCOS

While combined oral contraceptives are typically first-line for PCOS management (addressing irregular menses, androgen excess, and endometrial protection) 4, 5, the family history of early VTE shifts the risk-benefit balance decisively toward progestin-only methods.

The levonorgestrel IUD offers particular advantages in PCOS patients:

  • Provides effective contraception when other methods are contraindicated
  • Regulates abnormal uterine bleeding
  • Protects against endometrial hyperplasia and cancer risk associated with chronic anovulation 4
  • May be preferred over oral megestrol acetate for endometrial protection in obese PCOS patients 4

Thrombophilia Screening

Screening for thrombophilia should be performed given the first-degree family history before age 60 1. Testing should include:

  • Prothrombin time (PT)
  • Activated partial thromboplastin time (aPTT)
  • Antithrombin levels
  • Protein C and Protein S levels
  • Factor V Leiden
  • Prothrombin (FII) 20210A mutation

If documented thrombophilia is found, combined estrogen-progestin contraception becomes formally contraindicated (not just relatively contraindicated), and progestin-only methods remain the appropriate choice 1.

Common Pitfalls to Avoid

  • Do not prescribe combined oral contraceptives despite their benefits for PCOS symptoms - the thrombotic risk outweighs the benefits in this clinical scenario
  • Do not use DMPA - despite being progestin-only, it carries similar VTE risk to combined contraceptives 3
  • Do not skip thrombophilia screening - this is specifically indicated with first-degree family history before age 60 1
  • Do not assume all progestin-only methods are equivalent - levonorgestrel and desogestrel formulations have the best safety data, while DMPA does not 1, 3

Related Questions

What estrogen‑free contraceptive options are appropriate for a 19‑year‑old woman with a new left‑leg deep vein thrombosis who is taking apixaban (Eliquis)?
What birth control options are appropriate for a healthy 19‑year‑old woman who is not pregnant, does not smoke heavily, and has no history of thromboembolic disease, hypertension, migraine with aura, liver disease, or estrogen‑sensitive cancer?
What is the appropriate birth control method for a reproductive‑age woman with polycystic ovary syndrome, hypertension, obesity, and who is taking semaglutide (Wegovy)?
Should a 25-year-old woman with polycystic ovary syndrome (PCOS) using a levonorgestrel intrauterine device (IUD), who has mild acne, chin hirsutism, a 2 cm uterine fibroid, and laboratory evidence of insulin resistance, be treated with added estrogen (low‑dose combined oral contraceptive) to manage her hyperandrogenism?
Is it safe to have unprotected intercourse with a relative who is taking a combined oral contraceptive pill for polycystic ovary syndrome?
What components are measured in a standard lipid panel (lipid profile)?
Is a family history of venous thromboembolism a contraindication to combined hormonal contraception?
Is the standard lipid panel (total cholesterol, LDL‑cholesterol, HDL‑cholesterol, triglycerides, and calculated non‑HDL‑cholesterol) limited to the United States?
What ANA titer (dilution ratio) is considered positive for systemic lupus erythematosus and indicative of active disease?
What is the safest antibiotic for treating bacterial sinusitis in a patient receiving low‑dose methotrexate 2.5 mg daily?
What are the indications for thyroid‑stimulating hormone (TSH) screening, explained in layman's terms?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.